+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Glycated Haemoglobin (HbA1c) Testing Market

  • ID: 2913027
  • Report
  • 159 Pages
  • Roots Analysis
1 of 3
This report provides an exhaustive study of the growing market for HbA1c tests


  • A Menarini
  • Beckman Coulter
  • Diazyme Laboratories
  • Immatics Biotechnologies
  • Molecular Partners
  • Rohm
  • MORE
Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035.

With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. Furthermore, an efficient measurement of the condition can help lower the rate of serious complications, such as heart attack and stroke. HbA1c, adapted for clinical testing to monitor diabetes in 1990s, is one such test; it can monitor and give average glucose results over the past 120 days. The test offers significant advantages over usual blood glucose monitoring assays; these include no prior fasting requirement, high sample stability, low day-to-day variation and limited impact from external physical factors such as stress.

The adoption of HbA1c tests has gradually risen in the recent past. While the laboratory analyzers are likely to strengthen their existing position, a significant growth will also be driven by Point of Care (POC) devices. POC devices bring a change in overall diabetes management and the lifestyle of the individual. Compared to laboratory tests, they can be used at home or physician's office with instantaneous results and accuracy. In addition, considering the lifetime costs, POC testing is comparatively cheaper than laboratory testing. Increased efforts to overcome lack of awareness, especially in emerging markets, are also expected to drive adoption levels further.

With a large number of devices already in market for HbA1c testing and more to come in the future years, HbA1c market is likely to shape up much better in the coming years. We have strong reasons to believe that the overall market outlook will stay positive in the mid-long term.

The “Glycated Haemoglobin (HbA1c) Testing Market, 2014-2024” report provides an exhaustive study of the growing market for HbA1c tests. Amongst other things, the report identifies HbA1c analyzers that are currently available for point of care and laboratory testing, and the high level trends which are likely to govern the evolution of this market in the US, EU5 and BRICS countries. The report also provides a competitive landscape wherein we have identified the most efficient POC devices in the market based on parameters such as user friendliness and other technical details.

One of the key objectives of this report is to understand the current and future state of the HbA1c diabetes monitoring market across various regions worldwide. This is done by analyzing the following:

- Prevalence and growth of diabetes in different countries
- Number of patients going for HbA1c tests
- Frequency of HbA1c test per patient per year
- Variable price points
- Other technical details such as sample volume required, time taken for analysis, precision etc.

We have also provided a detailed view on the key drivers behind the growth of this market, likely challenges and upcoming threats under the SWOT framework. The base year for the report is 2014. The report provides mid -long term market forecasts for the period 2014 - 2024.
Note: Product cover images may vary from those shown
2 of 3


3 of 3


  • A Menarini
  • Beckman Coulter
  • Diazyme Laboratories
  • Immatics Biotechnologies
  • Molecular Partners
  • Rohm
  • MORE
Example Highlights:

- We identified 41 companies which are active in the HbA1c monitoring market. Amongst the 41 companies, nine manufacture both laboratory and POC analyzers. Except for the bigger companies which account for 41% of the overall industry, the nature of the market is quite fragmented.
- Currently, 108 HbA1c analyzers are commercially available. Of these, 71% are for laboratory use and the remaining 29% are for either home use or at physician's office.
- Specifically, for the POC testing, turbidimetry immunoassay and boronate affinity chromatography are the most commonly deployed principles (accounting for 50% and 35% of the POC devices respectively). The POC testing market has witnessed growing interest levels; acceptance is likely to rise further as a result of increased end-user convenience.
- For laboratory analyzers, Siemens, Beckman Coulter, Roche, Bio-Rad, Abbott, ELITech are some well-known players. The global distribution network of some of these players has positioned them to actively monetize this growing market.
- The overall market, in addition to an already well-established macro environment, will continue to benefit from continuous improvements in technology. In our base case, we expect the global HbA1c diabetes monitoring market to witness an annualized growth rate of 8.8%.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current scenario of HbA1c testing market and the likely mid-long term evolution.

Chapter 3 provides a general introduction to the HbA1c testing for diabetes diagnosis and monitoring. We have discussed key concepts behind the test, principles involved, applications, test recommendations, advantages and limitations of the test.

Chapter 4 provides an overview of the competition in the HbA1c market. The chapter provides an extensive list of point of care and laboratory analyzers for HbA1c testing. It also discusses the evolution and adoption of HbA1c tests in the US, EU5 and BRICS countries.

Chapter 5 focuses on the point of care HbA1c analyzers. It covers the general considerations for POC devices, the market analysis for home and physician HbA1c analyzers, product profiles of specific devices and key company profiles.

Chapter 6 includes the company profiles of five key companies manufacturing laboratory analyzers for HbA1c monitoring. The profiles cover overview of the company, financial information, manufacturing facilities, recent partnerships and the future outlook of these companies.

Chapter 7 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry's evolution.

Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the HbA1c diabetes monitoring market, capturing the key elements likely to influence future growth.

Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
Note: Product cover images may vary from those shown
4 of 3

- A Menarini
- AC Immune SA
- AT&T
- Aalto Scientific
- AbD Serotec
- Abbott
- Afinion
- Agappe
- Alere
- Alfa Wassermann
- Apex Bio
- ArkRay
- Ascletis
- Axis Shield
- Beckman Coulter
- Beijing Shining Sun
- Bio-Rad
- Biohermes
- Boditech
- CFR Pharmaceuticals
- Carolina Liquid
- Ceragem
- Chek Diagnostics
- Chiasma Inc.
- Ci-Co Healthcare
- Constitution Medical Inc.
- Convergent Technologies
- Diasys Diazyme
- Diazyme Laboratories
- Discuvia Ltd.
- Drew Scientific
- EKF Diagnostics
- ELITech
- Epocal
- Eurolyser
- FIOMI Diagnostics
- Freescale Semiconductors
- Hitachi
- Hitado
- Horiba Medical
- Human Diagnostics
- IDEV Technologies
- Immatics Biotechnologies
- Immco Diagnostics
- Inception Sciences Inc.
- Infopia
- Inovio
- Isis Pharma
- JANSSEN & Pharmacyclics
- Jeol
- Kyowa Medex
- LAB 21
- Mec Dynamics
- Merisant
- Mitsubishi
- Molecular Partners
- MorphoSys AG
- Myriad RBM, Inc.
- Nihon Kohden
- OptiMedica
- Ortho Clinical Diagnostics
- Oryzon Genomics
- Piramal Healthcare
- Pointe Scientific
- Polyphor Ltd.
- Prothena Corporation
- Quest Diagnostics
- Radiometer
- Randox laboratories
- Relay Technology Management
- Roche
- Rohm
- SD Biosensor
- Sakae Corporation
- Samsung
- Sanwa Kagaku Kenkyusho Co. ltd
- Sebia
- Sekisui Medical
- Shenzhen Lifotronic
- Siemens Healthcare
- Streck, Inc.
- Toshiba
- Tosoh Biosciences
- Trinity Biotech
- Tulip Reagents
- Valeant Pharmaceuticals
- Veropharm
- Versant Ventures
- Wako Pure Chemical industries
- Wiener laboratories

Note: Product cover images may vary from those shown